Intuitive Announces Executive Leadership Changes
19 Outubro 2021 - 3:45PM
Intuitive (Nasdaq: ISRG), a global technology leader in minimally
invasive care and the pioneer of robotic-assisted surgery, today
announced executive leadership changes that reflect the company’s
growth and plans for advancing minimally invasive care globally.
Intuitive has created two new functional organizations: Strategy
and Growth, and Global Business Services. These organizations will
be led by experienced senior executives who have spent decades with
Intuitive. Placing strategy and growth teams within a new
organization will create clearer prioritization and stronger
alignment for investments in support of the company’s long-term
growth plan. Given the opportunities for continued growth, the new
global business services organization will serve to align and scale
processes, manage multi-year IT roadmaps, better use enterprise
data for real-time decision-making, and maintain and execute global
facilities and maintenance roadmaps.
The following executives will begin their duties on Jan. 1,
2022:
- Marshall Mohr will assume the new role of Executive Vice
President, Global Business Services, where he will lead Intuitive’s
continued growth in infrastructure, processes, and systems and
facilities. He has served as Chief Financial Officer for more than
15 years.
- Jamie Samath will succeed Mohr to become Chief Financial
Officer, focusing on Intuitive’s financial performance, growth
objectives, and future fiscal trajectory. Samath has been with
Intuitive since 2013, managing most of the finance functions during
that time.
- Dave Rosa will assume the new role of Executive Vice President
and Chief Strategy & Growth Officer, leading efforts to
identify and realize long-term business opportunities, continuing
to build the value of Intuitive’s product offerings, and ensuring
customers clearly understand the value of Intuitive’s ecosystem in
creating successful minimally invasive care programs. Rosa has
been with Intuitive for more than 25 years, working across the
business.
- Henry Charlton will succeed Rosa in the role of Chief
Commercial Officer, overseeing global sales, regional marketing,
commercial learning and enablement, and services. He has been with
Intuitive for 18 years in the commercial organization.
“These are outstanding and proven leaders. I am confident they
will be effective in pursuing our goal to advance minimally
invasive care globally in a highly competitive environment,” said
Intuitive CEO Gary Guthart. “Their efforts will help us operate at
the larger scale our customers demand globally.”
With strong leadership in new and existing roles, Intuitive will
continue to drive measurable improvement in the Quadruple Aim for
customers—better patient outcomes, better patient and care team
experiences, and lower total cost to treat—and meet the future
challenges of healthcare.
Intuitive pioneered the field of robotic-assisted minimally
invasive surgery more than two decades ago with the da Vinci
surgical system. Since then, more than 8.5 million procedures have
been performed using da Vinci systems, with more than 55,000
surgeons worldwide trained on da Vinci systems.
About IntuitiveIntuitive (Nasdaq:
ISRG), headquartered in Sunnyvale, Calif., is a global
technology leader in minimally invasive care and the pioneer of
robotic-assisted surgery. As part of our mission, we believe that
minimally invasive care is life-enhancing care. Through ingenuity
and intelligent technology, we expand the potential of physicians
to heal without constraints.
Intuitive brings more than two decades of leadership in
robotic-assisted surgical technology and solutions to its
offerings, and develops, manufactures, and markets the
da Vinci® surgical system and the Ion™ endoluminal system
(available only in the U.S.).
About the da Vinci Surgical SystemThere are
several models of the da Vinci surgical system.
The da Vinci surgical systems are designed to help
surgeons perform minimally invasive surgery.
Da Vinci systems offer surgeons high-definition 3D
vision, a magnified view, and robotic and computer assistance. They
use specialized instrumentation, including a miniaturized surgical
camera and wristed instruments (i.e., scissors, scalpels and
forceps) that are designed to help with precise dissection and
reconstruction deep inside the body.
About IonIon is Intuitive’s robotic-assisted
platform for minimally invasive biopsy in the lung. The system
features an ultra-thin, ultra-maneuverable catheter that allows
navigation far into the peripheral lung and provides the
unprecedented stability necessary for precision in biopsy.
Forward-Looking StatementsThis press release
contains forward-looking statements, including statements regarding
executive leadership changes. These forward-looking statements
include statements regarding our future operational and financial
performance, product development, market position and business
strategy. These statements reflect the best judgment of the
Company's management and involve a number of risks and
uncertainties that could cause actual results to differ materially
from those suggested by the forward-looking statements. These
forward-looking statements should, therefore, be considered in
light of the risk factors under the heading “Risk Factors” in our
report on Form 10-K for the year ended December 31, 2020, as
updated by the Company’s other filings with the Securities and
Exchange Commission. Statements using words such as “estimates,”
“projects,” “believes,” “anticipates,” “plans,” “expects,”
“intends,” “may,” “will,” “could,” “should,” “would,” “targeted,”
and similar words and expressions are intended to identify
forward-looking statements. You are cautioned not to place undue
reliance on these forward-looking statements, which speak only as
of the date of this press release. The Company undertakes no
obligation to publicly update or release any revisions to these
forward-looking statements, except as required by law.
For more information, please visit the company’s website
at www.intuitive.com.
ContactUS/GLOBAL: Global Public
AffairsIntuitive Surgicalcorp.comm@intusurg.com+1-202-997-7373
Intuitive Surgical (NASDAQ:ISRG)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Intuitive Surgical (NASDAQ:ISRG)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024